Omixon Target HLA
Target H L A Ed it ion – get
the right answers
Omixon helps clinical, diagnostic and research labs to adopt NGS (Next Generation Sequencing) for the analysis of diagnostically important genomic target regions. Omixon Target has been developed for variant detection in targeted NGS data. Precision -Omixon Target HLA offers the highest possible HLA typing precision. Target results have been independently validated against Sanger SequenceBased Typing (SBT). Ease-of-Use – There is no need to be an expert in NGS analysis or to spend hours on manual editing of the sequence. Omixon HLA Typing can be run with just a few clicks of a mouse. Confidence in your results - You can visualize the results for the top allele candidates in the Omixon Target genome browser. Ambiguous results are clearly indicated.
Key Features –
About Omixon
n Fully automated, predominately unambiguous results without manual editing. n Accurate results with targeted, exome and whole genome data. n Works for Illumina, Ion Torrent and Roche 454. n High resolution typing of up to 30 loci. n Fast with high throughput.
Omixon’s team has extensive experience working in scientific laboratories such as Yale University, European Bioinformatics Institute, RIKEN, Steacie Institute and in pharmaceutical companies such as Novartis and AstraZeneca, and board members with executive experience in Myriad Genetics, Chemaxon and Yahoo. This is combined with a strong IT team with knowledge of genetics and past experience at IBM and Siemens.
The Target HLA Edition only includes HLA typing. You can upgrade to Target Standard or Target Pro for NGS data analysis. Support Omixon works collaboratively with clients to assist with their specific analysis needs. Your feedback and ideas for enhancing Omixon Target are most welcomed.
Visualization of HLA typing results
We are a dynamic and growing company supporting new ideas, innovation, and challenges in bioinformatics. For more information please email: [email protected].
Our Philosophy – our remedy to Sanger pain Sanger traces encode nucleotides of both alleles causing an inherent phase ambiguity that is normally resolved by statistical analysis and manual intervention from trained operators. Standard NGS analysis techniques are unsuitable for HLA typing due to the high diversity and the repetitive structural elements of the HLA region. NGS data can solve the ambiguity problem, while Omixon Target HLA solves the data analysis problem. Omixon uses an approach that searches the IMGT/ HLA1 database of known HLA allele sequences. The final result is a major reduction in ambiguity compared to Sanger results, saving a lot of manual work. 1
Robinson J, Mistry K, McWilliam H, Lopez R, Parham P, Marsh SGE The IMGT/HLA Database Nucleic Acids Research (2011) 39 Suppl 1:D1171-6 Robinson J, Malik A, Parham P, Bodmer JG, Marsh SGE: IMGT/HLA - a sequence database for the human major histocompatibility complex Tissue Antigens (2000), 55:280-287
the right answers
Omixon helps clinical, diagnostic and research labs to adopt NGS (Next Generation Sequencing) for the analysis of diagnostically important genomic target regions. Omixon Target has been developed for variant detection in targeted NGS data. Precision -Omixon Target HLA offers the highest possible HLA typing precision. Target results have been independently validated against Sanger SequenceBased Typing (SBT). Ease-of-Use – There is no need to be an expert in NGS analysis or to spend hours on manual editing of the sequence. Omixon HLA Typing can be run with just a few clicks of a mouse. Confidence in your results - You can visualize the results for the top allele candidates in the Omixon Target genome browser. Ambiguous results are clearly indicated.
Key Features –
About Omixon
n Fully automated, predominately unambiguous results without manual editing. n Accurate results with targeted, exome and whole genome data. n Works for Illumina, Ion Torrent and Roche 454. n High resolution typing of up to 30 loci. n Fast with high throughput.
Omixon’s team has extensive experience working in scientific laboratories such as Yale University, European Bioinformatics Institute, RIKEN, Steacie Institute and in pharmaceutical companies such as Novartis and AstraZeneca, and board members with executive experience in Myriad Genetics, Chemaxon and Yahoo. This is combined with a strong IT team with knowledge of genetics and past experience at IBM and Siemens.
The Target HLA Edition only includes HLA typing. You can upgrade to Target Standard or Target Pro for NGS data analysis. Support Omixon works collaboratively with clients to assist with their specific analysis needs. Your feedback and ideas for enhancing Omixon Target are most welcomed.
Visualization of HLA typing results
We are a dynamic and growing company supporting new ideas, innovation, and challenges in bioinformatics. For more information please email: [email protected].
Our Philosophy – our remedy to Sanger pain Sanger traces encode nucleotides of both alleles causing an inherent phase ambiguity that is normally resolved by statistical analysis and manual intervention from trained operators. Standard NGS analysis techniques are unsuitable for HLA typing due to the high diversity and the repetitive structural elements of the HLA region. NGS data can solve the ambiguity problem, while Omixon Target HLA solves the data analysis problem. Omixon uses an approach that searches the IMGT/ HLA1 database of known HLA allele sequences. The final result is a major reduction in ambiguity compared to Sanger results, saving a lot of manual work. 1
Robinson J, Mistry K, McWilliam H, Lopez R, Parham P, Marsh SGE The IMGT/HLA Database Nucleic Acids Research (2011) 39 Suppl 1:D1171-6 Robinson J, Malik A, Parham P, Bodmer JG, Marsh SGE: IMGT/HLA - a sequence database for the human major histocompatibility complex Tissue Antigens (2000), 55:280-287
